

Siemens Healthcare Diagnostics GmbH, SHS EMEA CEET QT, Siemensstrasse 90,  
1210 Vienna

Name M.A. Roland Ertl  
 Department SHS EMEA CEET QT  
 Telephone +43 51707-38274  
 Mobile +43 (664) 8011738274  
 E-mail roland.re.ertl@siemens-healthineers.com  
 Date May 18, 2020  
 Document Ref# ACHC20-06.A.OUS

**Urgent Field Safety Notice:**

**Dimension Vista® Systems**

**N-acetyl-p-benzoquinone imine (NAPQI) Interference with Dimension Vista® Enzymatic Creatinine (ECREA) Flex® reagent cartridge**

Dear Sirs,

Our records indicate that your facility may have received the following product:

**Table 1. Dimension Vista® Chemistry Systems affected product**

Assay	Test Code	Catalog Number	Siemens Material Number (SMN)	Lot Number
Enzymatic Creatinine	ECREA	K1270A	10700444	ALL

**Reason for Correction**

The purpose of this communication is to inform you of an interference identified with the product indicated in Table 1 above and to provide instructions on actions that your laboratory must take.

Siemens Healthcare Diagnostics has become aware that the presence of N-acetyl-p-benzoquinone imine (NAPQI), a metabolite of acetaminophen, may cause interference in certain chemistry assays when testing patient samples. Through spiking studies of NAPQI at 15 mg/L [101 µmol/L], Siemens observed a bias with Dimension Vista ECREA of approximately -15% at a creatinine concentration of 1.01 mg/dL [89 µmol/L]. This level of NAPQI correlates to a toxic level of acetaminophen. Titration experiments were subsequently performed to characterize the potential for interference at decreasing concentrations of NAPQI.

**Actions to be Taken by Siemens:**

The "Limitations of the Procedure" section of the Dimension Vista ECREA Instructions for Use (IFU) will be updated to indicate that *'N-acetyl-p-benzoquinone imine (NAPQI) is a metabolite of acetaminophen. NAPQI concentrations of approximately 10 mg/L correlating to toxic levels of acetaminophen demonstrates a ≤10% change in results. NAPQI concentrations greater than this may lead to falsely depressed results for patient samples.'*

Siemens Healthcare Diagnostics GmbH  
 Management: Wolfgang Koepl, Stefan Scheidler

Siemensstrasse 90  
 1210 Vienna  
 Austria

Tel.: +43 51707 0  
 healthcare.siemens.com

The information related to NAPQI provided in this letter supersedes the information in the current Dimension Vista ECREA IFU until updated.

The updated IFUs will be uploaded into Document Library where all registered users who opt in to receive alerts will be notified of the updated IFU.

## Risk to Health

There is negligible risk to health. At toxic levels of acetaminophen, NAPQI interference may lead to falsely depressed creatinine values, however the magnitude of the bias would not be expected to lead to a clinically significant difference in patient management.

## Actions to be Taken by the Customer:

- Be aware of the limitation indicated above.
- Please review this letter with your Medical Director.
- Complete and return the Field Correction Effectiveness Check Form attached to this letter within 30 days.
- If you have received any complaints of illness or adverse events associated with the products listed in Table 1, immediately contact your local Siemens Customer Care Center or your local Siemens technical support representative.

## Frequently Asked Questions:

### 1. Which other assays have been evaluated for NAPQI interference?

The assays indicated below were tested on the Siemens ADVIA Chemistry and Atellica CH systems. These assays have identical principles of procedure to the equivalent assays on the Dimension Vista system. No significant interference is expected on the following Dimension Vista assays: Cholesterol, Creatinine (Jaffe), Direct HDL, Lactic Acid, Lipase, Triglyceride, and Uric Acid.

Additionally, Direct and Total Bilirubin (DBIL and TBIL) were tested on the Dimension Vista system and showed no significant interference ( $\leq 10\%$  bias) for NAPQI concentrations of  $>15$  mg/L ( $101$   $\mu\text{mol/L}$ ) at sample concentrations similar to those published in each product's IFU.

### 2. Is the Jaffe Creatinine assay impacted in the presence of NAPQI?


Siemens testing has shown that the Jaffe methodology is not impacted by NAPQI interference as the Jaffe methodology uses different reagents and parameters than the ECREA assay.

Please retain this letter with your laboratory records and forward this letter to those who may have received this product.

We apologize for the inconvenience this situation may cause. If you have any questions, please contact your Siemens Customer Care Center or your local Siemens Technical Support representative.

Sincerely yours,

Siemens Healthcare Diagnostics GmbH



i.V. Dipl. Ing. Franz Schwarz  
Quality Management CEE



i.A. Dr.<sup>in</sup> Brigitte Gassner  
Product Manager Austria & SEE